1 PLOS ONE

2	Changes in Apolipoprotein A1 and B, Glucose Metabolism, and Skeletal Muscle Mass in
3	Peripheral Artery Disease after Endovascular Treatment: A Pilot Study
4	
4	$T_{1} = 1$; $T_{2} = 1$, $T_{1} = 1$, $T_{2} = 1$, $T_{2} = 1$, $T_{1} = 1$, $T_{2} = 1$, $T_{$
5	Takeshi Ikeda ¹ , Hidenori Komiyama ^{2*} , Tomoyo Miyakuni ¹ , Masamichi Takano ¹ , Masato
6	Matsushita ¹ , Nobuaki Kobayashi ¹ , Kuniya Asai ¹ , Wataru Shimizu ³ and Yasushi Miyauchi ¹
7	
8	¹ Cardiovascular Medicine, Medical School Chiba Hokusoh Hospital, 270-1613 Chiba, Japan.
9	
10	² Cardiovascular Medicine, Nippon Medical School Musashikosugi Hospital, 211-8533
11	Kanagawa, Japan.
12	
13	³ Cardiovascular Medicine, Nippon Medical School, Tokyo 113-8603, Japan.
14	
15	* Corresponding author
16	E-mail: <u>h-komiyama0317@nms.ac.jp</u>
17	
18	
19	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Abstract

21 Peripheral artery disease impairs walking and physical activity, resulting in further 22 loss of skeletal muscle. However, peripheral artery disease can be treated with endovascular 23 treatment. The thigh muscle has been shown to correlate with systemic skeletal muscle 24 volume. We assessed the changes in the metabolism of apolipoproteins A1 and B, blood 25 glucose, and thigh muscle mass after endovascular treatment in above-the-knee peripheral 26 artery disease where vessels supply the thigh muscle. Mid-thigh muscle volume was 27 measured with computed tomography before and at 6 months after endovascular treatment. 28 Apolipoproteins A1 and B, fasting blood glucose, post-load (75 g oral glucose tolerance test) 29 2 h-blood glucose, and glycated hemoglobin A1c (HbA1c) levels were measured 30 concomitantly. The relationships between changes in apolipoproteins A1, apolipoproteins B, 31 blood glucose, post-oral glucose tolerance test 2 h-blood glucose, Rutherford classification, 32 and gain or loss of thigh muscle were investigated. Thigh muscle mass did not correlate with 33 changes in apolipoproteins A1, B, fasting glucose, post-oral glucose tolerance test 2 h-blood 34 glucose, HbA1c, and Rutherford classification. Among patients with muscle gain postendovascular treatment, apolipoproteins A1 increased significantly, while apolipoproteins B 35 36 levels were similar. Post-oral glucose tolerance test 2 h-blood glucose levels decreased. 37 Preferable metabolic changes were observed in patients with skeletal muscle gain contrasted 38 with muscle loss.

39

40 Keywords: Apolipoproteins; Endovascular treatment; Glucose metabolism; Peripheral artery
41 disease; Risk factors; Skeletal Muscle

42

43 Introduction

Skeletal muscles modulate lipid and glucose metabolism, while lipids and glucose regulate skeletal muscles and vice versa [1,2]. Accordingly, lipids and glucose contribute to the development and progression of atherosclerosis; thus, the gain or loss of skeletal muscle is associated with the patients' vulnerability to cardiovascular events and all-cause mortality [3].

Using skeletal muscles to maintain physical activity [4] influences lipid metabolism [1,2]. Moreover, when receiving statins, the blood levels of apolipoprotein A1 (Apo A1) and B (Apo B) are reportedly significant predictors of myocardial infarction and all-cause mortality among patients with known coronary artery disease. Therefore, these markers may be more suitable for cardiovascular risk assessment [5]. Among atherosclerotic lipid and glucose parameters, glycated hemoglobin A1c (HbA1c) / A1 [6] and Apo A1 / B [7] have emerged as markers used to evaluate the atherosclerotic status of patients.

Among the atherosclerotic factors, glucose tolerance impairment carries a high risk of allcause mortality and cardiovascular events [8]. Glucose tolerance is usually evaluated by measuring blood glucose levels 2 h after loading 75 g of glucose, an examination otherwise known as the oral glucose tolerance test (OGTT). The association between impaired OGTT and atherosclerosis is reportedly stronger than that between fasting blood glucose (FBG) or HbA1c level and atherosclerosis [9]. Since skeletal muscles regulate the storage and delivery of glucose [10], gain or loss of skeletal muscle may be linked to glucose metabolism.

Additionally, Apo A1 reportedly increases glucose consumption in skeletal muscles and
improves glucose uptake, leading to amelioration of glucose tolerance [11,12]. In contrast,

high blood glucose down-regulates apolipoprotein M expression, influencing Apo A1 levels
[13,14]. Thus, Apo A1 and diabetes correlate bidirectionally, leading to a vicious cycle [15].

A previous report demonstrated that the volume of ischemic skeletal thigh muscle among 67 68 patients with above-the-knee peripheral artery disease (PAD) changes before and after 69 revascularization of occlusive iliofemoral arteries supplying thigh muscle after endovascular 70 treatment (EVT) [16]. PAD limits blood flow during ambulation, manifesting as intermittent 71 claudication (IC). In addition, PAD impairs the patients' physical activity, thereby 72 predisposing them to a sedentary lifestyle. A sedentary lifestyle is linked to further blood 73 sugar elevation and skeletal muscle loss through the inflammatory cascade [17,18]. PAD can 74 be treated by ameliorating IC and promoting physical activity after EVT [19]. IC is generally 75 classified according to the Rutherford classification [20]. However, the association between 76 metabolic parameters and skeletal muscle mass in PAD remains unclear.

This study aimed to investigate the relationships between Apo A1 and B levels, glucose metabolism, changes in symptoms according to Rutherford classification, and gain or loss of skeletal muscle mass among patients with above-the-knee PAD following EVT. The findings in this pilot study would pave the way for an enhanced understanding of the relationship between lipid and glucose metabolism in relation to skeletal muscle mass after EVT in a clinical setting.

83 Materials and Methods

84 Study design

85 This was a single-center, prospective, observational pilot study. Patients (14 with 86 ipsilateral and eight with bilateral lesions) with consecutive lower extremity above-the-knee

87 iliofemoral PAD with symptomatic IC classified according to the Rutherford criteria were 88 prospectively registered between 2016 and 2020. All patients were scheduled to undergo 89 elective EVT for iliofemoral lesions. To exclude and minimize the drug effects, prescribed 90 drug treatment was started at least 1 month before their enrollment in the study and 91 maintained throughout the remaining duration of the study.

Patients undergoing maintenance hemodialysis and critical ischemia were excluded from this study because these factors are related to excessive skeletal muscle loss [21,22]. The institutional review board of the Nippon Medical School Chiba Hokusoh Hospital approved this study (IRB number: 504) on April 25, 2016. The study was conducted in accordance with the tenets of the Declaration of Helsinki. Signed informed consent was obtained from all the patients. Fig 1 shows a flowchart of the study design.

98 Fig 1. Study design flowchart.

A total of 22 patients with lower extremity PAD with iliofemoral lesions were enrolled.
Blood tests, 75-g OGTTs, and computed tomography (CT) scans of the mid-thigh level of the
legs were performed upon admission and at 6 months after EVT.

102 Endovascular treatment

Patients intolerant to medications or contrast agents did not participate in the study. All patients were administered dual antiplatelet therapy for at least 7 days before EVT. At the start of the procedure, weight-adjusted intravenous heparin was administered with a target activated clotting time of more than 300 s. After crossing the guidewire through the target lesions, lesions were dilated using a suitable-sized balloon. The operator decided the size of the balloon. The stent diameter would exceed the reference diameter by approximately 1 mm. Post-dilatation was performed using a balloon shorter than the stent to avoid causing stent 110 edge dissection. Stent placement was performed if the flow limitation or residual stenosis was 111 more than 30% of the elastic recoil remaining in the target vessels. EPIC stents (Boston 112 Scientific, Massachusetts) and SMART stents (Cordis Co, Florida) were used during the 113 above procedure. Although efforts were made to complete the procedure with single stent placement, up to multiple stents were placed as governed by the necessity to achieve at least 114 115 30% of residual stenosis in the target lesions. Vascular patency after endovascular treatment 116 was evaluated by the ankle-brachial index (ABI) value, which would remain throughout the 117 study.

118 Measurement of the thigh muscle area

119 The skeletal muscles were assessed using the cross-sectional single-slice CT, which measured the muscle volume [23]. A 64-slice CT scan, using the Toshiba Aquilion 64 system 120 121 (Toshiba Medical Systems, Otawara, Japan), of the legs was performed before EVT and six months following the procedure. The cross-sectional area of the mid-thigh of both legs, 122 123 between the pubic symphysis and the inferior condyle of the femur, was measured [24]. The 124 thigh muscle area was measured using a commercial workstation (SYNAPSE; Fujifilm, 125 Tokyo, Japan) (Fig 2). Patients were further divided into skeletal muscle gain or loss groups 126 according to the change in the skeletal muscle area before and six months after EVT to 127 explore the impact of muscle on metabolisms.

Fig 2. Measurement of the mid-thigh muscle area. The thigh muscle area was measured at the mid-point cross-sections of 1 and 2.① Upper edge: mid-point of the upper margin of the greater trochanter and the lower margin of the femoral condyles.② Lower edge: mid-point of the upper margin of the patella and the lower margin of the patella

132 Measurement of Apo A1 and B

Serum concentrations of Apo A1 and Apo B were analyzed using immune nephelometry (Sekisui Medical Ltd., Tokyo, Japan) and measured on admission and at 6 months after EVT. The numeric values of HbA1c/Apo A1 and Apo B/Apo A1 were calculated according to the measured values.

137 OGTT and glycated HbA1c

Glycated HbA1c levels (normal limit <6.5%, 47 mmol/mol) were measured to evaluate glucose control. OGTT was performed to assess glucose tolerance. OGTT was performed in the morning upon breaking an overnight fast of 8–14 h. Blood samples were taken before consuming 75 g of glucose dissolved in 250–300 mL of water and at 30 min, 60 min, and 120 min after. OGTT was performed at the time of admission and 6 months after EVT.

144 ABI measurement

The ABI was measured using a Colin Wave-form analyzer (BP-203RPE III; Omron
Colin, Tokyo, Japan), according to the recommendations of the American Heart Association
[25]. The ABI was measured on admission and at 6 months after discharge.

148 Statistical analyses

Binary or categorical data are presented as frequencies or percentages. Continuous variables are expressed as means ± standard deviations or medians with interquartile ranges (IQRs). The Shapiro–Wilk test was used to assess whether variables were normally

152 distributed, while the chi-square test was used to assess dichotomous variables. The possible 153 correlation analyses were performed with Spearman correlation analysis among the changes 154 in the thigh muscle area after EVT, Apo A1 and B, fasting glucose (FBG), post 2 h-blood 155 glucose (OGTT-2hrBG), HbA1c, Rutherford classification, and the muscle areas in the midthigh before and 6 months after EVT. The graphical correlation matrix displaying the positive 156 157 and negative correlations between the changes in variables was obtained using the R package "Corrplot" (https://github.com/taiyun/corrplot). The concentrations of apolipoproteins and 158 159 glucose, along with the metrics of atherosclerotic parameters, were compared using a single-160 tailed paired t-test. The PWR (Basic Functions for Power Analysis) package was used to 161 analyze statistical power [26]. The statistical analyses were performed using the R software 162 (ver 3.6.2; The R Foundation for Statistical Computing, Vienna, Austria). P-values less than 163 0.05 were considered statistically significant.

164 **Results**

165 The clinical characteristics of the patients are summarized in Table 1. The mean age 166 of the patients was 72.4 ± 7.4 years. Most patients were male (91%), and characteristics such 167 as hypertension (82%) and dyslipidemia (86%) were prevalent. Baseline clinical symptoms were classified according to the Rutherford classification of PAD, which included the 168 169 following categories: category 1 (n = 11, 50.00%), category 2 (n = 10, 45.45%), and category 170 3 (n = 1, 4.55%). All patients received dual antiplatelet therapy before EVT. The location and 171 characteristics of the lesions are summarized in Table 2. There was no significant difference 172 between gain and loss of skeletal muscle. Clinical symptoms improved after EVT, which was 173 sustained during the study period. Six months after EVT, 82% (n = 18) of the patients were classified as category 0 and 18% (n = 4) as category 1. All patients were successfully 174 175 discharged the day after EVT without complications. Vascular patency was maintained

- throughout the study period and verified based on the ABI value after EVT (30 ischemic
- 177 lower limbs: before EVT 0.79 ± 0.14 , 6 months after EVT; 1.06 ± 0.16 , 14 non-ischemic
- 178 lower limbs: before EVT 1.01 ± 0.10 , 6 months after EVT; 1.05 ± 0.14).

179 Table 1. Baseline characteristics of the enrolled patients.

	All	Gain of skeletal	Loss of skeletal	P-value	
	All	muscle	muscle		
Number of patients	22	12	10		
Age (years)	72.4 ± 7.4	69.7 ± 7.5	75.6 ± 6.2	0.06	
Male	20 (91)	12 (100)	8 (80)	N. S	
Hypertension	18 (82)	10 (83)	8 (80)	N. S	
Dyslipidemia	19 (86)	10 (83)	8 (80)	N. S	
Diabetes	10 (45)	6 (50)	4 (40)	N. S	
HbA1c (%)	6.1 ± 0.7	$5.8 \pm 0.4*$	$6.5 \pm 0.8*$	0.0175*	
BMI	24.4 ± 3.5	25.1 ± 2.6	23.5 ± 4.4	N. S	
Past smoker	10 (45)	6 (50)	4 (40)	N. S	
Rutherford classification	1.5 ± 0.6	1.6 ± 0.5	1.5 ± 0.7	N. S	
Medications					
Dual antiplatelet therapy	22 (100)	12 (100)	10 (100)	N. S	
Aspirin	19 (86)	10 (83)	9 (90)	N. S	
Clopidogrel	9 (41)	5 (42)	4 (40)	N. S	
Cilostazol	6 (27)	2 (8)	4 (40)	N. S	
Prasugrel	6 (27)	4 (33)	2 (20)	N. S	
Statin	21 (95)	11 (92)	10 (100)	N. S	
ACE-I / ARB	22 (100)	12 (100)	10 (100)	N. S	

β-blocker	15 (68)	8 (67)	7 (70)	N. S

180 Data are presented as numbers (%). p * < 0.05, p ** < 0.01, Not significant (N. S). ACE-I, angiotensin-

- 181 converting enzyme inhibitor; ARB, angiotensin II receptor blocker. Statin regimen is listed in Supplementary
- 182 Table 1

183 Table 2. Location and characteristics of lesions.

Variables	All	Gain of skeletal	Loss of skeletal	p-value
variables	All	muscle	muscle	p-value
Location of lesions	N = 30	N = 17	N = 13	
Unilateral lesion	14 (64)	7 (58)	7 (70)	
				N.S
Bilateral lesions	8 (36)	5 (42)	3 (30)	
Iliac artery	16 (53)	10 (59)	6 (46)	N.S
Superficial femoral artery	9 (30)	6 (35)	5 (38)	N.S
Common femoral artery	1 (3)	0 (0)	1 (8)	N.S
Popliteal artery	3 (13)	1 (6)	0 (0)	N.S
Superficial + popliteal artery	1 (5)	0 (0)	1 (8)	N.S
TASC II classification				
Type A	17 (58)	10 (59)	7 (54)	N.S
Type B	6 (20)	3 (18)	3 (23)	N.S
Type C	2 (6)	0 (0)	2 (15)	N.S
Type D	5 (16)	4 (23)	1 (8)	N.S
Stent implantation	24 (80)	15 (88)	9 (70)	N.S

184 Data are presented as numbers (%). N.S, Not significant; TASC, Trans-Atlantic Intersociety Consensus

185 Thigh muscle area before and after EVT

- 186 The thigh muscle area of each patient changed after EVT (delta muscle area: 2.5±8.1
- 187 cm^2 , n = 22). Twelve patients gained skeletal muscle (delta thigh muscle area was positive:
- 188 8.4±5.9 cm²), and 10 patients lost skeletal muscle (delta thigh muscle area was negative: -
- 189 4.7±2.4 cm²) according to the change in the skeletal muscle area before and six months after
- 190 EVT (Table 3).

191

All (n=22)	Before	After 6 months	P-value	Delta value
Muscle area (cm ²)	239.8 ± 34.8	243.1 ± 40.8	0.21	2.5 ± 8.1
Apo A1 (mg/dl)	119.0 ± 17.4 **	129.6 ± 19.6 **	0.0027	10.7 ± 14.7
Apo B (mg/dl)	76.3 ± 17.3 *	81.3 ± 17.7 *	0.0404	5.0 ± 9.4
HbA1c (%)	6.1 ± 0.7	6.2 ± 0.8	0.74	0.073 ± 0.517
Apo B/Apo A1	0.65 ± 0.16	0.64 ± 0.16	0.11	-0.012 ± 0.081
HbA1c/Apo A1	0.053 ± 0.011 *	0.049 ± 0.011 *	0.0489	0.073 ± 0.517
Fasting Blood Glucose (mg/dl)	110.8 ± 20.4	116.6 ± 24.1	0.24	5.9 ± 22.5
2 hr-OGTT Blood Glucose (mg/dl)	193.5 ± 78.9	182.5 ± 79.6	0.29	-11.0 ± 48.0
Rutherford classification	1.5 ± 0.6	0.2 ± 0.4	p < 0.001	-1.4 ± 0.8

193 Table 3. Change in muscle area, Apolipoprotein A1, Apolipoprotein B, glucose metabolism, and Rutherford classification.

	Gain of skeletal muscle $n = 12$		12	Loss of skeletal muscle $n = 10$		
	before	6 months	P-value	before	6 months	P-value
Delta muscle area (cm ²)	NA	8.41 ± 5.93	NA	NA	-4.67±2.41	NA
Apo A1 (mg/dl)	121.8 ± 15.1 **	136.5 ± 19.5 **	p < 0.001	115.6 ± 20.1	121.4 ± 17.1	0.32
Apo B (mg/dl)	76.4 ± 19.2	80.5 ± 17.0	0.10	78.6 ± 19.8	82.3 ± 19.3	0.24
HbA1c (%)	5.8 ± 0.4	6.0 ± 0.4	0.97	6.5 ± 0.8	6.5 ± 1.1	0.50
Apo B/Apo A1	0.64 ± 0.17	0.60 ± 0.17	0.069	0.69 ± 0.19	0.68 ± 0.16	0.66
HbA1c/Apo A1	0.049 ± 0.007 **	0.045 ± 0.008 **	0.007	0.058 ± 0.004	0.054 ± 0.004	0.37
Fasting Blood Glucose (mg/dl)	110.2 ± 16.8	111.4 ± 22.2	0.83	111.5 ± 16.8	122.9 ± 25.9	0.094
2 hr-OGTT Blood Glucose (mg/dl)	189.7 ± 67.5	170.6 ± 69.7	0.075	198.1 ± 94.4	196.7 ± 91.8	0.93
Rutherford classification	1.6 ± 0.5 ***	0.3 ± 0.5 ***	p < 0.001	1.5 ± 0.7 ***	0.1 ± 0.3 ***	p < 0.001

197 p *<0.05, p **<0.01, p *** < 0.001 Not Applicable (NA).

198 Correlation analysis among the change in Apo A1, B, glucose

199 metabolism, intermittent claudication symptom, and skeletal

200 muscle mass

201 The analyses were performed to investigate possible correlations among changes in 202 the delta values of Apo A1 and B, fasting glucose, post 2 h-blood glucose, HbA1c, 203 Rutherford classification, and delta thigh muscle area after EVT. Delta muscle area and delta 204 value of each parameter were not significantly correlated (Figure 3). Equivalent correlation 205 analyses were performed in muscle gain and muscle loss patients (Supplementary Figures). 206 Among the measured parameters, delta Apo A1 correlated with delta HbA1c/Apo A1 (R = -0.76, p < 0.01) and delta B (R = -0.58, p = 0.005); delta Apo B correlated with B/A1 (R = 207 208 0.43, p=0.005); delta HbA1c correlated with HbA1c/Apo A1 (R = 0.58, p < 0.01); delta 209 HbA1c/Apo A1 correlated with delta Apo B/A1 (R = 0.45, p = 0.038) and delta Rutherford classification (R = 0.51, p = 0.015); delta FBG correlated with delta OGTT-2hr BG (R =210 211 0.49, p = 0.019) and Rutherford classification (R = 0.45, p = 0.034) (Fig 3).

212

213 Fig 3. Correlation matrix between delta values of Apo A1, B, fasting glucose, post 2 h-blood glucose,

214 HbA1c, Rutherford classification, and delta thigh muscle area after EVT.

215 A correlation matrix between delta values is drawn based on Spearman correlation analysis.

216 Correlation coefficients are colored according to the value combined with significant values,

and p-values ≥ 0.05 were considered insignificant and have been crossed out.

218 Glucose control and glucose tolerance before and after EVT

Overall, blood glucose levels did not change while fasting (pre: $110.8 \pm 20.4 \text{ mg/dL}$, 6 months: $116.6 \pm 24.1 \text{ mg/dL}$) and 2 h after OGTT (pre: $193.5 \pm 78.9 \text{ mg/dL}$; 6 months: 182.5 ± 79.6 mg/dL) (Figure 4). HbA1c did not change either (pre: $6.1 \pm 0.4\%$, 6 months: $6.2 \pm 0.4\%$) and was similar among patients with skeletal muscle gain (pre: $5.8 \pm 0.4\%$, 6 months: $6.0 \pm 0.4\%$) and loss (pre: $6.5 \pm 0.8\%$, 6 months: $6.5 \pm 1.1\%$) (Table 2).

226

227 Fig 4. Results of the 75-g OGTT. 4A: In all the patients, the blood glucose level did not change during fasting 228 (pre: 110.8 ± 20.4 mg/dL, 6 months: 116.6 ± 24.1 mg/dL), 30 min after OGTT (pre: 182.3 ± 38.4 mg/dL, 6 239 months: $181.3 \pm 41.2 \text{ mg/dL}$), 60 min after OGTT (pre: $210.5 \pm 59.5 \text{ mg/dL}$, 6 months: $205.2 \pm$ $\mathbf{B}_{\pm 78.9 \text{ mg/dL}, 6 \text{ months: } 182.5 \pm 79.6 \text{ mg/dL}). 4B: In}$ 232 56.6 mg/dL), and 2 h after OGTT (pre: 193.5 233 patients with gain of skeletal muscle, the blood glucose level did not change during fasting (pre: 110.2 ± 16.8 234 mg/dL, 6 months: 111.4 ± 22.2 mg/dL), 30 min after OGTT (pre: 184.2 ± 40.0 mg/dL, 6 months: 178.5 ± 47.7 235 mg/dL), and 60 min after OGTT (pre: 210.2 ± 65.7 mg/dL, 6 months: 205.8 ± 67.7 mg/dL) but decreased 2 h 236 after OGTT (pre: 189.7 \pm 67.5 mg/dL, 6 months: 170.6 \pm 69.7 mg/dL, p = 0.0754). 4C: In patients with loss of 237 skeletal muscle, the fasting glucose level was increased (pre: $111.5 \pm 16.8 \text{ mg/dL}, 6 \text{ months}: 122.9 \pm 25.9$ 238 mg/dL, p = 0.0939), but there was no alteration in 30 min after OGTT (pre: 180.1 ± 38.5 mg/dL, 6 months: 239 $184.7 \pm 34.1 \text{ mg/dL}$), 60 min after OGTT (pre: $211.0 \pm 54.7 \text{ mg/dL}$, 6 months: $204.5 \pm 43.3 \text{ mg/dL}$), and 2 h 240 after OGTT (pre: $198.1 \pm 94.4 \text{ mg/dl}$, 6 months: $196.7 \pm 91.8 \text{ mg/dl}$).

С

In patients with skeletal muscle gain, the glucose level did not change during fasting (pre: 110.2 ± 25.0 mg/dL, 6 months: 111.4 ± 22.2 mg/dL) but tended to decrease 2 h after OGTT (pre: 189.7 ± 67.5 mg/dL, 6 months: 170.6 ± 69.7 mg/dL, p = 0.0754) (Figure 4B). In patients with loss of skeletal muscle, their fasting glucose level tended to increase (pre: 111.5 ± 16.8 mg/dl, 6 months: 122.9 ± 25.9 mg/dl, p = 0.0939), and their blood glucose levels 2 h after

246 OGTT remained unaltered (pre: 198.1 ± 94.4 mg/dL, 6 months: 196.7 ± 91.8 mg/dL) (Figure
247 4C).

248 Change of Apo A1 and B before and after EVT

Overall, Apo A1 levels increased after EVT (pre: $119.0 \pm 17.4 \text{ mg/dL}$, 6 months: 129.6 ± 19.6 mg/dL, p = 0.0027). Apo A1 levels significantly increased in patients with skeletal muscle gain (pre: $121.8 \pm 15.1 \text{ mg/dL}$, 6 months: $136.5 \pm 19.5 \text{ mg/dL}$, p < 0.001) (Table 2). Apo B levels did not change in patients with either skeletal muscle gain (pre: $76.4 \pm$ 19.2 mg/dL, 6 months: $80.5 \pm 4.9 \text{ mg/dL}$) or skeletal muscle loss (pre: $78.6 \pm 19.8 \text{ mg/dL}$, 6 months: $82.3 \pm 19.3 \text{ mg/dL}$) (Table 2).

255 Atherosclerotic metrics of Apo B/Apo A1 and HbA1c/Apo A1

256 Overall, Apo B/Apo A1 levels (pre: 0.66 ± 0.18 , 6 months: 0.64 ± 0.16) decreased in 257 patients with skeletal muscle gain (pre: 0.64 ± 0.18 , 6 months: 0.60 ± 0.17 , p = 0.0693) but did not change significantly in those with skeletal muscle loss (pre: 0.69 ± 0.19 , 6 months: 258 259 0.68 ± 0.16). In addition, HbA1c/Apo A1 significantly decreased (pre: 0.053 ± 0.011 , 6 260 months: 0.049 ± 0.011 , p = 0.0489) (Table 2). However, the decrease was only significant among patients with skeletal muscle gain (pre: 0.049 ± 0.007 , 6 months: 0.045 ± 0.008 , p =261 262 0.0070) but not in those with skeletal muscle loss (pre: 0.058 \pm 0.013, 6 months: 0.054 \pm 263 0.012) (Table 2).

264 **Discussion**

The major findings in this study are as follows: first, there was no significant correlation between change in muscle area and Apo A1 and Apo B levels, glucose metabolism, and Rutherford classification. The change in Apo A1 levels negatively correlated with HbA1c/A1

and B/A1 changes. Second, when the patients were categorized as having muscle gain or loss based on the thigh muscle CT after EVT, Apo A1 levels were significantly increased in patients with skeletal muscle gain after EVT. Additionally, Apo B levels did not change in patients with skeletal muscle gain or loss. Third, glucose tolerance improved muscle gain, while fasting glucose levels decreased in patients with muscle loss.

273 Changes in Apo A1 and B, glucose metabolism, intermittent

274 claudication symptom, and skeletal muscle mass

275 While there was no significant correlation between delta muscle area and delta values of Apo A1 and B, glucose metabolisms, and Rutherford classification, Apo A1 levels were 276 277 significantly increased in patients with skeletal muscle gain. Since exercise would increase 278 Apo A1 levels [27], successful EVT can promote physical activity in patients with PAD, 279 which is associated with the increase in Apo A1 levels in the present study. While no specific 280 exercise was implemented in this study, only a modest change in physical activity of walking 281 after EVT can modify the metabolism to anti-atherosclerotic [28,29]. Apo B levels did not 282 change significantly in patients with skeletal muscle gain or loss since all the enrolled 283 patients with PAD underwent statin therapy, which might explain why there was no change.

According to the current clinical practice guidelines, initiation of statin therapy is recommended to prevent subsequent cardiovascular events in established cardiovascular disorders [30]. The efficacy of statin therapy has been well established in numerous studies. The statin on-treatment blood level of Apo A1 and Apo B were significant predictors of myocardial infarction and all-cause mortality in patients with known coronary artery disease and might be more suitable for assessing cardiovascular risk [5]. Apo A1 functions as a major component of the high-density lipoprotein complex to clear cholesterol from white blood

cells inside the artery walls [31]. WBCs are less likely to become lipid overloaded, transform into foam cells, and die, contributing to the progression of atherosclerosis [31]. Additionally, among patients treated with statins, an increase in Apo A1 levels was associated with a reduced risk of major cardiovascular events, while high-density lipoprotein (HDL) cholesterol was not [32]. Conversely, Apo B particles are atherogenic and entrapped within the arterial walls. They initiate and cause persistent inflammation, thus resulting in advanced atherosclerosis [33].

298 We previously demonstrated that skeletal muscle mass increases after EVT, specifically in 299 patients with normoglycemic control (HbA1c < 6.5) before EVT [34]. Thus, if the PAD 300 patients were grouped based on skeletal muscle volume gain or loss, patients with skeletal 301 muscle gain would be considered closer to normoglycemia than those with loss of skeletal 302 muscle. HbA1c is clinically used to monitor glycemic control among diabetic patients [35]. 303 None of the patients in the present study were obliged to cut caloric intake or seek dietary 304 guidance, as apparent from the unchanged HbA1c values [36]. Glucose tolerance was 305 measured among enrolled patients with 75-g OGTT. Blood glucose levels 2 h after 75-g 306 OGTT have been associated with atherosclerosis more than fasting glucose or HbA1c levels 307 [9]. Blood glucose is regulated by glucose transporters (GLUTs). Among glucose 308 transporters, GLUT4 plays a central role in glucose homeostasis [37]. In rodent models, 309 target disruption of glucose transporters in muscles causes insulin resistance and glucose 310 intolerance [38]. Additionally, glucose transporters in the thigh muscle are upregulated by 311 exercise, which improves glucose tolerance [39]. Therefore, muscles function as organs that 312 control serum glucose levels. In the present study, there was no correlation between the 313 change in skeletal muscle volume and glucose metabolism; however, PAD patients with 314 skeletal muscle gain tended to show improved glucose tolerance, while those with skeletal 315 muscle loss had a deteriorated fasting glucose level. Additionally, while Apo A1 improves

316 glucose tolerance [11,12], high blood glucose levels downregulate Apo A1 expression. In 317 patients with skeletal muscle gain, Apo A1 levels increased significantly, and glucose 318 tolerance tended to improve, while blood glucose levels were high in patients with muscle 319 loss. The results of this study are consistent with those of previous reports [11,12].

320 Metrics of atherosclerosis: HbA1c/Apo A1 and Apo B/Apo A1

321 Apolipoproteins may be atherogenic or anti-atherogenic and serve as biological 322 markers. A recent study has shown that the ratio of HbA1c/A1 after myocardial infarction 323 helps predict all-cause mortality and major adverse cardiac events, including nonfatal 324 myocardial infarction, cardiac death, and revascularization [6]. In addition, numerous studies 325 have demonstrated that the Apo B/Apo A1 ratio can be used as a parameter of atherosclerotic 326 conditions [5]. Recent studies have shown that Apo B/Apo A1 are inadequate to assess the 327 recurrent risk of cardiovascular events among on-statin-treated patients [40,41]. In the present 328 study, although there was no significant correlation between changes in skeletal muscle and 329 delta HbA1c/Apo A1 and Apo B/Apo A1, delta Apo A1 significantly correlated with delta 330 HbA1c/Apo A1 and Apo B/Apo A1. Accordingly, Apo A1 modified the metrics of 331 atherosclerosis (HbA1c/Apo A1 and Apo B/Apo A1). Thus, the change in Apo A1 after EVT 332 would impact atherosclerotic conditions. Additionally, HbA1c/A1 was significantly 333 decreased among patients with muscle gain after EVT. However, the previous studies lacked 334 a consecutive long-term follow-up [5,6], and long-term changes should be further studied.

335 Study limitations

This study has several limitations. First, even though the calculated statistical power was adequate in this preliminary study, recruitment of a larger number of participants estimated based on the data from this pilot study would strengthen the results further. Second,

339 the observational period was six months, which was relatively short. Observation for a more 340 extended period is needed to assess whether the multifaceted favorable effect of EVT 341 continues. Third, we recruited patients with PAD with mild claudication and excluded 342 patients with below-the-knee lesions, hemodialysis treatment, and critical limb ischemia. 343 Recent research has revealed that patients with PAD are more likely diabetic, frequently 344 undergoing hemodialysis treatment, and mostly older than patients with coronary artery disease, suggesting that patients with PAD visit clinicians only when cardiovascular 345 346 pathology has already advanced [42]. The early detection of PAD, as in this study, can confer 347 significant benefits and delay atherosclerotic progression [43]. Fourth, we did not recruit 348 patients with neuropathic muscle atrophy, which was common in patients with diabetic 349 neuropathy [44] or lumbar disc herniation [45], as their presentations could partially overlap 350 with PAD. Including patients with typical IC would exclude such subsets of patients. Fifth, 351 we did not implement duplex ultrasound assessment on vascular patency, which represents a 352 more accurate diagnostic test than resting ABI assessment. Sixth, we did not implement a 353 specific exercise regimen among the PAD cohort due to institutional limitations. The effect 354 of supervised exercise after EVT will be explored in a future study. Finally, we did not 355 objectively evaluate the patient's normal and subsequent physical activity levels. Levels of 356 physical activity are associated with changes in metabolism after EVT, which were only 357 based on the Rutherford criteria in this study and were derived from subjective symptoms. To 358 date, physical activity assessment is largely derived from questionnaires and interviews [46, 359 47]. Capturing and incorporating the patients' objective baseline physical activity and 360 changes during the study with new technology such as wearable monitoring devices [48] 361 would reveal the confounding factor influencing the impact of EVT on the metabolism of 362 patients with PAD in the upcoming clinical trials [49].

363 Conclusions

This study revealed the unidentified relationships between metabolic parameters and skeletal muscle mass in clinical settings. EVT had a positive impact on apolipoproteins and glucose metabolisms in patients with PAD. Notably, in patients with skeletal muscle gain after EVT, an increase in anti-atherosclerotic apolipoprotein Apo A1 levels and possible improvement in glucose tolerance are expected. Extended studies are needed to fill the knowledge gap regarding the regulation of metabolism and skeletal muscle mass.

370 Acknowledgments

We would like to express our overflowing gratitude to all the staff of Nippon Medical
School, Chiba Hokusoh Hospital Cardiovascular Centre, for their valuable therapeutic and
technical support.

374 Author Contributions

TI: HK: conception and design, analysis, interpretation of data, and drafting of manuscript. TM, MT, MM, NK, KA, MM, HT, WS, and YM: conception and design, critical revision of manuscript. All authors have read and approved the final manuscript.

378

379 **References**

 Lipina C, Hundal HS. Lipid modulation of skeletal muscle mass and function. *Journal of cachexia, sarcopenia and muscle.* 2017;8:190-201.
 Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. *Lipids in health and disease.* 2017;16:1-8.

384 3. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. *The Lancet.* 2019;393:2636-2646.

385	4.	Fletcher GF, Landolfo C, Niebauer J, Ozemek C, Arena R, Lavie CJ. Promoting physical activity
386		and exercise: JACC health promotion series. Journal of the American College of Cardiology.
387		2018;72:1622-1639.
388	5.	Sniderman A, Furberg C, Keech A, et al. Apolipoproteins versus lipids as indices of coronary
389		risk and as targets for statin treatment. The Lancet. 2003;361:777-780.
390	6.	Song F, Zhou Y, Zhang K, Liang Y-F, He X, Li L. The role of the plasma glycosylated
391		hemoglobin A1c/Apolipoprotein Al ratio in predicting cardiovascular outcomes in acute
392		coronary syndrome. Nutrition, Metabolism and Cardiovascular Diseases. 2021;31:570-578.
393	7.	Bodde MC, Hermans MP, Jukema JW, et al. Apolipoproteins A1, B, and apoB/apoA1 ratio are
394		associated with first ST-segment elevation myocardial infarction but not with recurrent events
395		during long-term follow-up. Clinical Research in Cardiology. 2019;108:520-538.
396	8.	Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and
397		cardiovascular disease: updated meta-analysis. <i>bmj</i> . 2020;370.
398	9.	Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M.
399		Postchallenge plasma glucose and glycemic spikes are more strongly associated with
400		atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23:1830-1834.
401	10.	Das DK, Graham ZA, Cardozo CP. Myokines in skeletal muscle physiology and metabolism:
402		recent advances and future perspectives. Acta Physiologica. 2020;228:e13367.
403	11.	Tang S, Tabet F, Cochran BJ, et al. Apolipoprotein AI enhances insulin-dependent and insulin-
404		independent glucose uptake by skeletal muscle. Scientific reports. 2019;9:1-9.
405	12.	Fritzen AM, Domingo-Espín J, Lundsgaard A-M, et al. ApoA-1 improves glucose tolerance by
406		increasing glucose uptake into heart and skeletal muscle independently of AMPKa2. Molecular
407		metabolism. 2020;35:100949.
408	13.	Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlbaäck B. Isolation and
409		characterization of human apolipoprotein M-containing lipoproteins. Journal of lipid research.
410		2006;47:1833-1843.
411	14.	Zhang X, Jiang B, Luo G, Nilsson-Ehle P, Xu N. Hyperglycemia down-regulates apolipoprotein
412		M expression in vivo and in vitro. Biochimica et Biophysica Acta (BBA)-Molecular and Cell
413		Biology of Lipids. 2007;1771:879-882.

414	15.	Xepapadaki E, Nikdima I, Sagiadinou EC, Zvintzou E, Kypreos KE. HDL and type 2 diabetes:
415		the chicken or the egg? <i>Diabetologia</i> . 2021;64:1917-1926.
416	16.	Miyakuni T, Komiyama H, Takano M, et al. A preliminary pilot study investigating the impact
417		of endovascular treatment on leg muscle volume in peripheral artery disease and its relation to
418		baseline glycemic control. Nutrition, Metabolism and Cardiovascular Diseases. 2021;31:269-276.
419	17.	MacDonald TL, Pattamaprapanont P, Pathak P, et al. Hyperglycaemia is associated with
420		impaired muscle signalling and aerobic adaptation to exercise. Nature Metabolism. 2020;2:902-
421		917.
422	18.	Hirata Y, Nomura K, Senga Y, et al. Hyperglycemia induces skeletal muscle atrophy via a
423		WWP1/KLF15 axis. JCI insight. 2019;4.
424	19.	Muscella A, Stefàno E, Marsigliante S. The effects of exercise training on lipid metabolism and
425		coronary heart disease. American Journal of Physiology-Heart and Circulatory Physiology.
426		2020;319:Н76-Н88.
427	20.	Hardman RL, Jazaeri O, Yi J, Smith M, Gupta R. Overview of classification systems in
428		peripheral artery disease. Seminars in interventional radiology. Vol 31: Thieme Medical
429		Publishers; 2014:378-388.
430	21.	Kittiskulnam P, Carrero JJ, Chertow GM, Kaysen GA, Delgado C, Johansen KL. Sarcopenia
431		among patients receiving hemodialysis: weighing the evidence. Journal of cachexia, sarcopenia
432		and muscle. 2017;8:57-68.
433	22.	Pizzimenti M, Meyer A, Charles AL, et al. Sarcopenia and peripheral arterial disease: a
434		systematic review. Journal of Cachexia, Sarcopenia and Muscle. 2020;11:866-886.
435	23.	Ma KF, Berends B, Vedder IR, et al. Quantification of muscle mass in the legs of patients with
436		peripheral arterial occlusive disease: associations between volumetric and cross-sectional single-
437		slice measurements for identification of atrophy and focal sarcopenia. J Cardiovasc Surg
438		(Torino). 2019;60:672-678.
439	24.	Bernard S, LeBlanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic
440		obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:629-634.
441	25.	Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: Beyond secondary
442		prevention: identifying the high-risk patient for primary prevention: noninvasive tests of
443		atherosclerotic burden: Writing Group III. Circulation. 2000;101:E16-22.

444	26.	Champely S, Ekstrom C, Dalgaard P, Gill J, Weibelzahl S, Anandkumar A, et al. Package 'pwr'.
445		R package version. 2018:1-2.
446	27.	Schwartz RS. Effects of exercise training on high density lipoproteins and apolipoprotein AI in
447		old and young men. Metabolism-Clinical and Experimental. 1988;37:1128-1133.
448	28.	Fletcher GF, Landolfo C, Niebauer J, Ozemek C, Arena R, Lavie CJ. Promoting Physical
449		Activity and Exercise: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:1622-1639.
450	29.	Moghetti P, Balducci S, Guidetti L, et al. Walking for subjects with type 2 diabetes: A systematic
451		review and joint AMD/SID/SISMES evidence-based practical guideline. Nutr Metab Cardiovasc
452		Dis. 2020;30:1882-1898.
453	30.	Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol
454		and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the
455		JUPITER trial. The Lancet. 2009;373:1175-1182.
456	31.	Vanags LZ, Wong NKP, Nicholls SJ, Bursill CA. High-Density Lipoproteins and Apolipoprotein
457		A-I Improve Stent Biocompatibility. Arterioscler Thromb Vasc Biol. 2018;38:1691-1701.
458	32.	Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and
459		apolipoprotein AI in relation to risk of cardiovascular events among statin-treated patients: a
460		meta-analysis. Circulation. 2013:CIRCULATIONAHA. 113.002670.
461	33.	Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and
462		Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4:1287-1295.
463	34.	Miyakuni T, Komiyama H, Takano M, et al. A preliminary pilot study investigating the impact
464		of endovascular treatment on leg muscle volume in peripheral artery disease and its relation to
465		baseline glycemic control. Nutr Metab Cardiovasc Dis. 2021;31:269-276.
466	35.	Care D. 6. Glycemic targets: standards of medical care in diabetes—2019. <i>Diabetes Care</i> .
467		2019;42:861-70.
468	36.	O'Connor S, Turcotte A-F, Gagnon C, Rudkowska I. Increased Dairy Product Intake Modifies
469		Plasma Glucose Concentrations and Glycated Hemoglobin: A Systematic Review and Meta-
470		Analysis of Randomized Controlled Trials. Advances in Nutrition. 2019;10:262-279.
471	37.	Huang S, Czech MP. The GLUT4 glucose transporter. Cell metabolism. 2007;5:237-252.
472	38.	Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectively
473		in muscle causes insulin resistance and glucose intolerance. Nat Med. 2000;6:924-928.

474	39.	Hughes VA, Fiatarone MA, Fielding RA, et al. Exercise increases muscle GLUT-4 levels and
475		insulin action in subjects with impaired glucose tolerance. Am J Physiol. 1993;264:E855-862.
476	40.	Liem A, van De Woestijne A, Roeters van Lennep H, Zwinderman A, van der Steeg W, Jukema
477		J. ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated
478		patients. Current medical research and opinion. 2008;24:359-364.
479	41.	Hermans M, Jukema J, Schalij M, et al. Apolipoprotein A1, B and apoB/apoA1 ratio are
480		associated with first ST-segment elevation myocardial infarction but not with recurrent events
481		during long term follow-up. Optimization of secondary prevention and risk stratification in patients
482		with coronary heart disease. 2019;108:59.
483	42.	Takahara M, Iida O, Kohsaka S, et al. Diabetes mellitus and other cardiovascular risk factors in
484		lower-extremity peripheral artery disease versus coronary artery disease: an analysis of
485		1,121,359 cases from the nationwide databases. Cardiovasc Diabetol. 2019;18:155.
486	43.	Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk
487		assessment: a report of the task force of the foot care interest group of the American Diabetes
488		Association, with endorsement by the American Association of Clinical Endocrinologists.
489		Diabetes Care. 2008;31:1679-1685.
490	44.	Volpato S, Bianchi L, Lauretani F, et al. Role of muscle mass and muscle quality in the
491		association between diabetes and gait speed. Diabetes Care. 2012;35:1672-1679.
492	45.	Grovle L, Haugen AJ, Natvig B, Brox JI, Grotle M. The prognosis of self-reported paresthesia
493		and weakness in disc-related sciatica. Eur Spine J. 2013;22:2488-2495.
494	46.	Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly
495		(PASE): development and evaluation. Journal of clinical epidemiology. 1993;46:153-162.
496	47.	Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina
497		Questionnaire: a new functional status measure for coronary artery disease. Journal of the
498		American College of Cardiology. 1995;25:333-341.
499	48.	Bayoumy K, Gaber M, Elshafeey A, et al. Smart wearable devices in cardiovascular care: where
500		we are and how to move forward. Nature Reviews Cardiology. 2021:1-19.
501	49.	Polonsky TS, McDermott MM. Lower Extremity Peripheral Artery Disease Without Chronic
502		Limb-Threatening Ischemia: A Review. JAMA. 2021;325:2188-2198.

504 Supporting Information

- 505 S1 Fig. The correlational matrix between delta values of Apo A1, B, fasting glucose, post 2 h-blood
- 506 glucose, HbA1c, Rutherford classification, and delta thigh muscle area after EVT in skeletal muscle gain
- 507 patients.
- 508 S2 Fig. The correlational matrix between delta values of Apo A1, B, fasting glucose, post 2 h-blood
- 509 glucose, HbA1c, Rutherford classification, and delta thigh muscle area after EVT in skeletal muscle loss
- 510 patients.
- 511 S1 Table. Statin regimen of the study cohort.

Figure 1.




Figure 2.




Figure 3.




Figure 4.

